Drug info language
Switches all medical info on this page (labels, indications, leaflet) without changing the rest of the interface.
Highly Regulated (List I)Translated
HEPATITIS B IMMUNOGLOBULIN P BEHRING
1000UI/5ML/IM Injectable Solution (Pre-filled Syringe)/IMMUNOGLOBULINE HUMAINE DE L'HEPATITE B
ManufacturerVerified lab
CSL BEHRING
Public retail price
N/ADZD
Identification
- Active ingredient (INN)
- IMMUNOGLOBULINE HUMAINE DE L'HEPATITE B
- Internal code
- 13 V 506
- Country of Origin
- Germany
- Pharmaceutical form
- IM Injectable Solution (Pre-filled Syringe)
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/1 seringue pre-remplie de 5ml
Clinical View
Highly Regulated (List I)
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
- in the event of accidental contamination in unimmunized subjects (including when vaccination is incomplete or unknown).
- in haemodialysis patients waiting for vaccination effectiveness.
- in the newborn in the case of a mother carrying hepatitis B virus.
- in patients who have not developed an immune response after vaccination against hepatitis B virus (antibodies against hepatitis B not detectable) and who need continuous protection against this disease.
Associated Conditions
The patient is not exposed to a certain amount of HBS.
The patient is exposed to a certain amount of HBS.
Mechanism of Action
Pharmacotherapeutic group: immunes and immunoglobulins, human hepatitis B immunoglobulin, ATC code: J06BB04.
This medicinal product contains mainly immunoglobulins
G (IgG).
This preparation has a specific antibody activity directed against the surface antigen of hepatitis B virus (Ag HBs).
Adverse Effects
- Immune system disease: hypersensitivity, anaphylactic shock.
- Nervous system disease: headache.
- Heart disease: tachycardia.
- Vascular disorders: hypotension.
- Gastrointestinal disorders: nausea, vomiting.
- Skin and subcutaneous tissue disease: rash, pruritus, erythema.
- Musculoskeletal and systemic disorders: arthralgia.
- General disorders and administration site conditions: fever, malaise, chills.
- At the injection site: oedema, pain, erythema, induration, heat, pruritus, rash Pediatric population The frequency, type and severity of adverse reactions in children should be the same as in adults For safety related to transmissible agents.